In the present study, we aim to find out the effect of oral Risedronate a Bisphosphonate in clinical outcome of Perthes disease. In this randomized control trial, after ethical clearance and informed consent formalities, total 60 patients were analyzed. All the patients chosen in the study were in the Herrings A and B. The VAS score range of motion measured at different follow-ups and Deformity Index was measured at 2 years follow up. At 2 years final follow-up, Deformity index showed a statistically significant head shape preservation leading to increased range of motion of the involved hip. There was no statistically significant difference in pain by risedronate. Therefore we concluded that there is a definite role of oral risedronate in preservation of head shape with improved range of motion of hip joint in perthes disease.
